(TBI). Rituximab was approved as part of combination chemotherapy for MCL in Ontario in 2003, and RM was approved in 2006. Therefore, rituximab was incorporated into pre-and post-ASCT management at these time points. Before 2006 patients received no maintenance, while after this date, RM was offered to all patients unless contraindicated. MCL diagnosis was confirmed according to current criteria [5] . All histopathologic subtypes were eligible. Patients had to meet typical eligibility criteria for ASCT (age ≤ 65 years, stage II-IV disease, performance status ECOG 0-1 at time of transplantation, no significant medical comorbidity).
Staging was routinely performed with bone marrow aspirate and biopsy (morphology, flow cytometry, absence of cyclin D1), and whole-body CT scan. FDG-PET was not routinely performed, and upper and lower endoscopy as clinically indicated. Response was evaluated according to Cheson criteria [6] . Patients were typically assessed midway (CT scan following four cycles of CHOP or RCHOP, and after two cycles each of RCHOP/RDHAP) and at the end of induction with repeat imaging (FDG-PET restaging not routinely performed), and bone marrow assessment (if initially involved).
Peripheral blood stem cells (PBSC) were mobilized using cyclophosphamide (2000 mg/m 2 day 1) and etoposide (200 mg/m 2 day 1-3) with filgrastim 10 μg/kg/day starting on day 6, and leukapheresis starting day 13. PBSC graft minimum and target cell dose were 2.0 × 10 6 CD34+ cells/ kg and 5.0 × 10 6 CD34+ cells/kg, respectively. Over the years considered in this study, different conditioning regimens were used (Table 1) . Response assessment post ASCT was performed 3 months after stem cell infusion. For post-transplant RM, rituximab 375 mg/m 2 was administered weekly for four doses at 3 and 9 months, or once every 3 months for eight doses. These different schedules were chosen based on data from literature showing effectiveness of RM four times weekly at 3 and 9 months after fludarabine, cyclophosphamide, and mitoxantrone (FCM +/−R) in relapsed MCL [7] or based on local funding for indolent lymphoma (every 3 months dosing).
Progression-free survival (PFS) and OS were calculated from the date of ASCT. PFS and OS rates were estimated using the Kaplan-Meier method. Univariable (UVA) and multivariable (MVA) analyses of PFS and OS were performed using the Cox proportional hazard model. Variables included were: age, MCL subtype, MIPI risk category, primary chemotherapy regimen, stem cell dose, use of RM post ASCT.
Data regarding patient characteristics, response to treatment, and stem cell collection are summarized in Supplementary Tables 1 and 2 . Ninety-eight patients were included in this analysis (Table 1) . Induction chemotherapy was CHOP for 14 patients (14%), R-CHOP for 57 (59%), and R-CHOP/R-DHAP for 27 (27%). CR was obtained in 44/98 (44%) patients after induction. HDT was melphalan + etoposide for 63 patients (64%; 47/63 patients received also TBI), cytarabine + melphalan for 30 (31%; 30/30 received Min minimum, max maximum, MCL mantle cell lymphoma, pts patients, TBI total body irradiation, PFS progression-free survival, CBV cyclophosphamide + BCNU + etoposide, OS overall survival a Etoposide 60 mg/kg on day −4, melphalan 160 mg/m 2 on day −3, and TBI 12 Gy in six fractions of 2 Gy twice daily on days -2, -1 and 0 b TBI 10 Gy in six fractions (twice daily over 3 days) followed by cytarabine 1500 mg/m 2 IV every 12 h for 2 days (total dose 6000 mg/ m No patients experienced fatal toxicity during induction chemotherapy or transplant. Ninety-seven of 98 patients were evaluable for renal toxicity: during the induction treatment 13/97 patients (13%) experienced creatinine increase (grade 1: 5 patients; grade 2: 4 patients; grade 3: 4 patients); five of these patients received DHAP as part of induction. Although 5/5 patients had normal creatinine values at diagnosis, 3/5 had risk factors (3/3 hypertension, 1/3 diabetes mellitus). Six out of 13 patients who had experienced renal toxicity during HDT or in the first 3 months post ASCT, subsequently developed chronic kidney impairment (CKI; RCHOP: 3/13 patients, 23%; R-CHOP/R-DHAP: 3/13 patients, 23%). At 1 year post-ASCT CKI was grade 1 in 1/6 patients (R-CHOP), grade 2 in 3/6 (2 R-CHOP, 1 R-DHAP), and grade 3 in 2/6 patients (2/2 R-DHAP). Overall, 6/97 (6%) evaluable patients persisted with CKI after ASCT (R-CHOP: 3/57 patients, 5%; R-CHOP/R-DHAP: 3/27 patients, 11%).
Data regarding post-ASCT maintenance were available for 95/98 patients. Twenty-three patients (24%) were simply observed while 72/95 patients (76%) underwent RM. Data regarding RM schedules were available for 56/72 patients: 12/56 patients received rituximab once every 3 months for 2 years, while 44/56 patients received 4 weekly rituximab administrations at 3 and 9 months post ASCT. All the patients undergoing RM completed all the planned infusions of rituximab without significant toxicity.
The median follow-up for the entire cohort was 3.2 years (0.1-14.1; Table 1 ). Median PFS and OS were 8.2 years (95% CI: 4.63-NR) and 9.16 years (95% CI: 7.31-NR), respectively (Fig. 1 ). Patient receiving RM had a significant improvement in both median PFS (p < 0.001) and OS (p = 0.009; Fig. 1 ).
Twenty-nine of 95 evaluable patients relapsed (31%; 3 patients lost to follow-up).
MIPI (high-risk) was statistically significant for PFS in UVA but not at MVA. Age ≥ 60 years and stem cell dose > 5.0 × 10 6 /kg were both statistically significant at UVA for OS, but only age remained significant in MVA. Neither factor was statistically significant for PFS. RM remained significant in MVA for both PFS and OS.
At last follow-up, 24/98 patients (24.5%) had died, with 3/24 being in CR (non-relapse mortality, NRM: 3%). Causes of death were MCL (21), graft-versus-host disease post-allogeneic SCT for secondary myelodysplastic syndrome (1), and infection post-allogeneic SCT for relapsed MCL (1); unknown (1) . Six patients developed second malignancies: myelodysplastic syndrome (3), rectal cancer (1), thyroid cancer (1), and breast cancer (1) .
ASCT is a standard of care for eligible MCL patients based on data showing significant PFS improvement over standard chemotherapy. ASCT was adopted as standard therapy at our institution based on the results of a matchedpair analysis [8] of advanced-stage MCL patients treated with conventional chemotherapy and patients receiving ASCT followed by RM, suggesting that patients treated with ASCT-rituximab had significantly better PFS.
The impact of rituximab in the induction therapy was addressed by Lenz et al. [9] , with R-CHOP being superior to CHOP in terms of overall response rate (94% vs. 75%; p = 0.0054) and CR rate (34% vs. 7%; p = 0.00024). Further data from several authors highlight the importance of adding cytarabine to the induction regimen [10, 11] . Delarue et al. [11] reported an increase in the CR rate from 12% after R-CHOP to 57% after R-DHAP.
The role of different pre-ASCT HDT regimens was addressed by the same authors [11] . TBI has long been felt to be important in MCL given the inherent radiosensitivity of the disease [12] . With all of the limitations due to limited sample and varied treatment regimens, patients receiving TBI in our cohort had an improved PFS (p = 0.045). Toxicity from TBI was acceptable with no acute NRM. Previous observations reported superior efficacy of TBI without increased incidence of secondary hematological malignancies [13] , although contradictory data are available [14] .
The phase III LyMa trial showed that RM (once every 2 months for 3 years) following four courses of R-DHAP plus ASCT (without TBI) prolongs EFS, PFS, and OS [15] . The optimal schedule for RM post ASCT is not known. In our monocentric study, we observed a benefit of RM for both PFS and OS. In this data set, age and primary chemotherapy were not associated with significant differences in OS, while patients with high-risk MIPI had significantly inferior OS despite the use of ASCT.
There are limitations to our findings. The induction therapy was not uniform although most of our patients received R-CHOP or R-CHOP/R-DHAP. All R-CHOP/R-DHAP patients received RM and depth of remission pretransplant could be a confounding factor for the effect of RM. Follow-up was longer in the observation group than in the RM group.
In conclusion, the outcomes of responding patients following ASCT appear superior to previous strategies, and RM improved both PFS and OS. In our opinion, RM should be routinely offered post ASCT. The inclusion of TBI in the conditioning regimen appears effective and well tolerated.
